Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3205 - Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer

Date

11 Sep 2017

Session

Poster display session

Presenters

Jingjing Chen

Citation

Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390

Authors

J. Chen, I. Guccini, D. Di Mitri, D. Brina, A. Alimonti

Author affiliations

  • Molecular Oncology, Institute of Oncology Research, 6501 - Bellinzona/CH
More

Resources

Abstract 3205

Background

Metabolism in cancer serves to provide energy and key biomolecules that sustain cell growth, a process that is frequently accompanied by decreased mitochondrial use of glucose. Importantly, metabolic intermediates including mitochondrial metabolites are central substrates for post-translational modifications at the core of cellular signalling and epigenetics. However, the molecular means that coordinate the use of mitochondrial metabolites for anabolism and nuclear protein modification are poorly understood.

Methods

We constructed prostate specific Pten; Pdha1 double knockout mice by crossing transgenic mice with flox elements flanking exon 8 of Pten gene and exon 4 and exon 5 of Pdha1 gene. Gene expression profiling analysis and metabolic analysis between Pten; Pdha1 double knockout and Pten knockout tumours were performed to investigate the metabolic pathways altered upon Pdha1 inactivation. Lipidomics analysis between these two genotypes of tumours were performed to reveal the difference on the lipid and cholesterol ester species in response to Pdha1 inactivation.

Results

We found that genetic and pharmacological inactivation of Pyruvate Dehydrogenase A1 (PDHA1), a subunit of pyruvate dehydrogenase complex (PDC) that regulates mitochondrial metabolism inhibits prostate cancer development in different mouse and human xenograft tumour models. Intriguingly, we found that lipid biosynthesis was strongly affected in prostate tumours upon PDC inactivation. Mechanistically, we found that nuclear PDC controls the expression of Sterol regulatory element-binding transcription factor (SREBF) target genes by mediating histone acetylation whereas mitochondrial PDC provides cytosolic citrate for lipid synthesis in a coordinated effort to sustain anabolism. In line with the oncogenic function of PDC in prostate cancer, we find that PDHA1 and the PDC activator, Pyruvate dehydrogenase phospatase 1 (PDP1), are frequently amplified and overexpressed at gene and protein level in these tumours.

Conclusions

Taken together, our findings demonstrate that mitochondrial and nuclear PDC sustains prostate tumourigenesis by controlling lipid biosynthesis thereby pointing at this complex as a novel target for cancer therapy.

Clinical trial identification

Legal entity responsible for the study

Molecular Oncology, Institute of Oncology Research

Funding

IBSA foundation

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.